Micromolar Concentrations of Sodium Arsenite Induce Cyclooxygenase-2 Expression and Stimulate p42/44 Mitogen-Activated Protein Kinase Phosphorylation in Normal Human Epidermal Keratinocytes
Authors:
Open Access
- 12 May 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 79 (2) , 248-257
Abstract
Based on evidence that arsenic modulates proinflammatory events that are involved in skin carcinogenecity, we hypothesized that in normal human epidermal keratinocytes (NHEK) arsenic increases expression of the procarcinogenic enzyme cyclooxygenase-2 (COX-2) and that this occurs via specific mitogen and stress signaling pathways. To test this hypothesis, NHEK were exposed to sodium arsenite, and COX-2 expression, prostaglandin E2 (PGE2) secretion, mitogen-activated protein kinase (MAPK) phosphorylation, and DNA synthesis were quantified. Inhibitors of p42/44 and p38 MAPKs were used to evaluate the contribution of mitogen and stress signaling to the modulation of COX-2. Our results demonstrate that arsenite (0.005–5 μM) elevates COX-2 expression, PGE2 secretion (2.5–5 μM), and DNA synthesis (1–5 μM). Arsenite stimulated p42/44 but not p38 MAPK phosphorylation (2.5 μM), responses different than those produced by epidermal growth factor. Inhibition of mitogen-activated protein kinase kinase (MAPKK) and p38 MAPK using PD98059 (20 μM) and SB202190 (5 μM), respectively, attenuated the elevation of COX-2 protein induced by arsenite, whereas physiological concentrations of three COX-2 inhibitors (e.g., NS-398, piroxicam, and aspirin) reduced arsenite-stimulated DNA synthesis. These data indicate that arsenite elevates COX-2 in NHEK at the transcriptional and translational levels as well as increases PGE2 secretion. Compounds that inhibit COX-2 expression and activity may be useful in the scientific study, prevention, and treatment of arsenic skin carcinogenesis and deserve further investigation.Keywords
This publication has 39 references indexed in Scilit:
- Mechanism of arsenic carcinogenesis: an integrated approachMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2003
- The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E2 secretion by cultured human adult microglia: Implications for Alzheimer’s diseaseBrain Research, 2002
- Is COX-2 inhibition a panacea for cancer prevention?International Journal of Cancer, 2001
- Inhibition of p38 MAP Kinase Activity Up-Regulates Multiple MAP Kinase Pathways and Potentiates 1,25-Dihydroxyvitamin D3-Induced Differentiation of Human Leukemia HL60 CellsExperimental Cell Research, 2000
- Sodium Arsenite-Induced Dysregulation of Proteins Involved in Proliferative SignalingToxicology and Applied Pharmacology, 2000
- Low Levels of Arsenic Trioxide Stimulate Proliferative Signals in Primary Vascular Cells without Activating Stress Effector PathwaysToxicology and Applied Pharmacology, 1999
- Metabolism and Toxicity of Arsenicals in Cultured Cells1999
- NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesionsGeneral Pharmacology: The Vascular System, 1993
- Carcinogenicity, teratogenicity and mutagenicity of arsenicMutation Research/Reviews in Genetic Toxicology, 1980
- PHARMACOKINETICS OF PIROXICAM IN MAN1978